Monocytes to Apolipoprotein A1 ratio is associated with metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus
Authors:
Open Access
- 28 December 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Abstract
The monocyte-to-Apolipoprotein A1 ratio (MAR) emerges as a potentially valuable inflammatory biomarker indicative of metabolic dysfunction-associated fatty liver disease (MASLD). Accordingly, this investigation primarily aims to assess the correlation between MAR and MASLD risk. A cohort comprising 957 individuals diagnosed with type 2 diabetes mellitus (T2DM) participated in this study. The relationship between MAR and MASLD was analyzed through binomial logistic regression analysis and restricted cubic splines (RCS). Furthermore, a comparative assessment of MAR and monocyte to high-density lipoprotein ratio (MHR) in identifying MASLD efficacy was conducted using receiver operating characteristic curve analysis. Remarkably, even after adjusting for metabolic parameters and hepatic functional markers, MAR stood out as an independent predictor for MASLD (OR 1.58, 95% CI 1.36–1.84; P < 0.001) and displayed a nonlinear positive association with MASLD risk according to RCS analysis (P for nonlinearity and overall < 0.001). Notably, MAR exhibited superior diagnostic accuracy for identifying MASLD compared to MHR (AUC: 0.772 vs 0.722, P < 0.001). In summary, MAR emerges as a promising inflammatory indicator for MASLD, demonstrating potential as a valuable screening tool to bolster the management of MASLD within the T2DM population.Keywords
This publication has 41 references indexed in Scilit:
- Impact of NAFLD and its pharmacotherapy on lipid profile and CVDAtherosclerosis, 2022
- New inflammatory biomarkers (lymphocyte and monocyte percentage to high-density lipoprotein cholesterol ratio and lymphocyte to monocyte percentage ratio) and their association with some cardiometabolic diseasesWiener klinische Wochenschrift, 2022
- Apolipoprotein-AI and AIBP synergetic anti-inflammation as vascular diseases therapy: the new perspectiveMolecular and Cellular Biochemistry, 2021
- Interaction between high-density lipoproteins and inflammation: Function matters more than concentration!Advanced Drug Delivery Reviews, 2020
- Standards of medical care for type 2 diabetes in China 2019Diabetes/Metabolism Research and Reviews, 2019
- Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosisHepatology, 2018
- Monocyte inflammatory profile is specific for individuals and associated with altered blood lipid levelsAtherosclerosis, 2017
- Innate Immunity and Inflammation in NAFLD/NASHDigestive Diseases and Sciences, 2016
- Impact of Systemic Inflammation and Autoimmune Diseases on apoA-I and HDL Plasma Levels and Functions2014
- Association of peripheral total and differential leukocyte counts with metabolic syndrome and risk of ischemic cardiovascular diseases in patients with type 2 diabetes mellitusDiabetes/Metabolism Research and Reviews, 2006